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Abstract
One-fifth of all newly diagnosed breast cancer cases are ductal carcinoma in situ (DCIS), but little
is known about DCIS risk factors. Recent studies suggest that some subtypes of DCIS (high grade,
or comedo) share histopathologic and epidemiologic characteristics with invasive disease, while
others (medium or low grade, or non-comedo) show different patterns. To investigate whether
reproductive and hormonal risk factors differ among comedo and non-comedo types of DCIS and
invasive breast cancer, we used a population-based case-control study of 1808 invasive and 446
DCIS breast cancer cases and their age and race frequency-matched controls (1564 invasive and
458 DCIS). Three or more full-term pregnancies showed a strong inverse association with
comedo-type DCIS (odds ratio (OR) = 0.53, 95% confidence interval (CI) = 0.30, 0.95) and a
weaker inverse association for non-comedo DCIS (OR = 0.73, 95% CI = 0.42, 1.27). Several risk
factors (age at first full-term pregnancy, breastfeeding, and age at menopause) demonstrated
similar associations for comedo-type DCIS and invasive breast cancer, but different associations
for non-comedo DCIS. Ten or more years of oral contraceptive showed a positive association with
comedo-type DCIS (OR = 1.31, 05% CI 0.70, 2.47) and invasive breast cancer (OR = 2.33, 95%
CI 1.06, 5.09), but an inverse association for noncomedo DCIS (OR = 0.51, 95% CI 0.25-1.04).
Our results support the theory that comedo-type DCIS may share hormonal and reproductive risk
factors with invasive breast cancer, while the etiology of non-comedo DCIS deserves further
investigation.
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INTRODUCTION
Carcinoma in situ (CIS) of the breast, a classification for malignant cells that have not
moved beyond the epithelium to invade the basal membrane, is further categorized as either
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lobular (LCIS) or ductal (DCIS), depending on its location (1). In addition, DCIS can be
classified into comedo (high grade) and non-comedo (medium or low grade) subtypes based
on histopathologic characteristics such as pattern of necrosis and maximum nuclear
diameter. Both biologic and epidemiologic evidence suggest that some DCIS develops into
invasive disease while other forms of DCIS may not progress to invasive breast cancer
(IBC) (2-7).
Age-adjusted incidence rates for DCIS increased from 2.3 per 100,000 females in 1973 (8)
to 15.8 per 100,000 in 1992 (9). The most dramatic increases have occurred since 1983, with
a 17.5% annual increase in incidence rates between 1983 and 1992 compared with increases
of 3.9% annually from 1973 to 1983 (9). Separate studies in Detroit (10), Connecticut (11),
Vaud, Switzerland (12), and Florence, Italy (13) have shown that most of this increase was
due to the introduction of screening mammography in the early 1980s and subsequent
increases in its use in women age 40 and over. However, since 1992, the proportional
change in incidence rates for DCIS has slowed, especially for comedo DCIS (14). In
addition, 80% of all DCIS diagnosed in the US since 1980 were non-comedo type.
Whether or not DCIS lesions found through increased detection will progress to invasive
disease is unknown. It is generally believed that comedo-type DCIS is more similar
histologically to invasive disease than is the non-comedo-type. Studies of women diagnosed
with concomitant DCIS and invasive breast cancer or with IBC following a DCIS diagnosis
have reported that higher grade DCIS is associated with higher grade IBC (15-20).
Estimated DCIS prevalence rates based on autopsy studies of women who died from causes
other than breast cancer range from 0.2% to 14.7%, compared with 0-1.8% for invasive
breast cancer (21). Therefore, some in situ lesions may take much longer to develop invasive
characteristics or may never become invasive during a woman's lifespan. Because of the
uncertainties regarding DCIS progression, most lesions are treated aggressively.
Understanding the differences in risk factor profiles, if any, between DCIS subtypes is a first
step toward identifying which lesions may be more likely to progress to invasive disease.
Many of the accepted risk factors for invasive breast cancer involve hormonal exposures,
particularly to estrogen, whether directly through exogenous use (oral contraceptives,
hormone replacement therapy) or indirectly through reproductive events such as timing of
menarche and menopause, pregnancy, and lactation. Previous studies have found nulliparity,
late age at first pregnancy, early menarche, late menopause, no lactation, and exogenous
hormone use associated with invasive breast cancer (22). The connection between estrogen
and in situ breast cancer is less clear.
We examined known hormonal and reproductive risk factors for invasive breast cancer to
determine whether they are risk factors for DCIS, and to determine whether risk factors
differ for comedo and non-comedo DCIS subtypes. Odds ratios for DCIS as well as for
DCIS subtypes (comedo, non-comedo) were compared directly with those of invasive breast
cancer in the same North Carolina study population.
MATERIALS AND METHODS
Study design
The Carolina Breast Cancer Study (CBCS) is a population-based case-control study of in
situ and invasive breast cancer in African-American (AA) and Caucasian women (23).
Eligible study participants were residents of 24 contiguous counties of eastern and central
North Carolina who were aged 20 to 74 at time of diagnosis (cases) or selection (controls).
Women with first breast cancer diagnoses (in situ or invasive) were identified through a
rapid-ascertainment system in conjunction with the North Carolina Central Cancer Registry
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(24), and controls were located via computerized lists from the Department of Motor
Vehicles (under age 65) and the Health Care Finance Administration (age 65 and over).
Controls were frequency-matched to cases on race and 5-year age intervals.
Invasive cases were enrolled in two phases, between 1993 and 1996 (Phase 1) and from
1996 through 2001 (Phase 2), and were over-sampled for African-Americans and younger
age (20-49 years). Specifically, a process of randomized recruitment using predetermined
probabilities (25) was used to balance four groups based on age and race: younger African
Americans, older African-Americans, younger non-African Americans, and older non-
African Americans, described in detail elsewhere (23).
In situ case enrollment occurred between 1996 and 2001 and included pure DCIS, DCIS
with microinvasion to a depth of 2mm, and LCIS. All in situ cases matching the age and
geographic constraints mentioned above were eligible for the study, with no oversampling
on race or age.
Study population
A total of 705 carcinoma in situ (CIS) cases were identified during the enrollment period. Of
these, 50 were ineligible or deceased, leaving 655 eligible cases. Five cases could not be
contacted, physicians refused participation for 51 cases, and 58 declined to participate.
Therefore, 541 CIS cases participated resulting in an overall response rate (participants /
eligible cases) of 82.6%. Thirty-eight participants were excluded from the current analysis
because they completed only a mini questionnaire that did not include hormonal or
reproductive questions, along with 28 cases of pure LCIS and 29 cases of DCIS with
microinvasion, leaving 446 pure DCIS cases. Of the 940 DCIS controls sampled, 122 were
ineligible or deceased, 88 could not be located, and 197 refused participation. A total of 458
DCIS controls completed the full questionnaire, resulting in an overall response rate among
eligible controls of 65.2%.
Risk factor distributions were similar for invasive breast cancer cases enrolled in both
phases of data collection, so data for all IBC cases from Phase 1 and Phase 2 were combined
to maximize statistical power, for a total of 2704 identified cases. Of those, 201 were
ineligible or deceased, 64 could not be contacted, physicians refused participation for 175,
and 361 declined to participate, resulting in an overall response rate among eligible cases of
76.0%. In addition, 95 invasive breast cancer cases were excluded because they completed
only the mini questionnaire, leaving 1808 IBC cases for the current analysis. A total of 3600
controls for invasive breast cancer cases were identified, of which 427 were ineligible or
deceased, 689 could not be located, and 739 declined participation, resulting in an overall
response rate for eligible controls of 55.0%. Controls who did not complete the full
questionnaire were excluded (n=175), leaving 1564 controls for the IBC study analyses.
Central pathology review
Initial DCIS diagnosis was assigned by the referring physician and verified for 446 cases by
a pathologist employed by the CBCS based on a review of pathology reports and H&E
stained slides. Less than two percent of the cases reviewed were classified as something
other than DCIS based on the CBCS pathologist's evaluation. DCIS subtype classification
was based on a detailed microscopic examination of an H&E stained slide for each case.
Cases classified as comedo DCIS had a comedo-type pattern of necrosis and two of the
following three characteristics: large or very large nuclear diameter (>2 times the diameter
of a red blood cell), vesicular nuclear pleomorphism, or prominent nucleoli. All other DCIS
cases were classified as non-comedo. Fifty-six DCIS cases were not subtyped, leaving a
total of 393 DCIS cases (163 comedo and 230 non-comedo) for DCIS subtype analyses.
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Data collection and description of variables of interest
Trained female nurses conducted in-person interviews at the woman's home or another
agreed upon location using a structured questionnaire. Topics covered by the questionnaire
include sociodemographic factors, menstrual and pregnancy history, medical history,
hormone use, family history of cancer, physical activity and occupational history. The nurse
measured height and weight at the time of the interview; all other questions were answered
via self-report. Participants were given visual aids to assist with recall, such as pictures of
common prescription and non-prescription drugs and calendars to pinpoint dates. Average
time between diagnosis and interview was 198 days for DCIS cases and 145 days for
invasive breast cancer cases.
Main hormonal and reproductive risk variables included parity (categorized for analyses as
no full-term pregnancies, one, two, three or more), age at first full-term pregnancy (<26,
26+), lactation (never, ever), oral contraceptive (OC) use (never, ever) and duration of OC
use (<5 years, 5 to 10 years, >10 years), use of hormone replacement therapy (HRT) (never,
ever), duration of HRT use (<5 years, 5-10 years, >10 years) and recency of HRT use
(never, current, former 5+ years since last use), age at menopause (<40, 40-49, 50+), and
age at menarche (≤11, 12, 13, 14+). Participants who classified their race as American
Indian/Eskimo, Asian or Pacific Islander, or Other (n=13 for DCIS, n=53 for invasive) were
combined with Whites, resulting in two race categories: African-American and non African-
American. Age at the time of interview was computed from self-reported birth date and
included in all analyses as a continuous variable. Women under age 50 were considered
postmenopausal if they had undergone natural menopause (menstruation cessation), bilateral
oophorectomy, or irradiation of the ovaries. In women aged 50 or older, menopausal status
was assigned based on menstruation cessation. Natural and surgical menopause were
combined for analysis, since duration of estrogen exposure was the main focus.
Statistical analyses
The main outcome variable was ductal carcinoma in situ, which included all cases of pure
DCIS. Differences in exposure and outcome variable distributions by case-control status and
histological type were evaluated using chi-square tests generating two-sided p-values. Odds
ratios and 95 percent confidence intervals were computed using unconditional logistic
regression. Tests for trend were conducted by evaluating the p-value for the beta coefficient
where exposure was coded as an ordinal variable. Case-control analyses were conducted for
all data in order to estimate main effects for the risk factors, comparing each case group
(DCIS or invasive) to frequency-matched controls. In addition to analyses for all DCIS cases
combined, univariate and multivariate analyses were conducted for DCIS cases stratified on
histopathologic subtype (comedo vs. non-comedo) and case-case analyses were used to
identify factors with different relationships between comedo and non-comedo DCIS (26).
All regression models contained an offset term to account for the sampling probabilities
used to identify eligible cases and controls (25). If removal of the covariate from the model
resulted in a 10 percent or larger change in stratum-specific regression coefficients, that
variable was considered a confounder and remained in the final model.
All evaluations of potential effect measure modification and confounding were conducted on
the in situ and invasive datasets separately. The resulting model included covariates that met
modeling criteria for either dataset in order to facilitate direct comparisons between in situ
and invasive model estimates. All statistical analyses were conducted using SAS version 8.2
(SAS Institute Inc., Cary, NC, USA).
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A total of 904 women participated in the DCIS study, of which 18.1 percent were African-
American (N=164). The mean age of all DCIS cases combined (55.16 ± 11.07 SD) and of
comedo and non-comedo cases (Table 1) was slightly higher than that of controls (54.46 ±
10.26 SD), and a higher percentage of DCIS cases than controls were African-American
(21.1% of all DCIS combined vs. 15.3% of controls). Comedo DCIS cases were slightly
more likely to have a first degree family member with breast cancer and a college education
and were more often in the highest income bracket than non-comedo cases.
Invasive breast cancer cases and controls were slightly younger than their DCIS
counterparts, as reflected in both mean and median ages. IBC cases and controls included
larger proportions of African-Americans than corresponding DCIS cases and controls
because African-Americans were over-sampled for the IBC study. Phase II IBC cases had a
higher percentage of African-American participants than phase I IBC cases.
Age and race were included in all multivariate models along with the offset terms to account
for probability sampling by age and race age. No other covariates met our criteria for
inclusion in models as a confounder, and there was no significant odds ratio modification by
any of the evaluated covariates at a 0.05 alpha level.
DCIS and invasive cases vs. controls
A first full-term birth under age 26 was inversely associated with both DCIS and invasive
breast cancer. An inverse association with parity strengthened with number of full-term
pregnancies in the DCIS group but remained relatively constant for IBC, regardless of
number of pregnancies (Table 2). Ever having breastfed was not associated with DCIS but
was inversely associated with invasive cancer.
Increasing duration of OC use was positively associated with invasive breast cancer but not
DCIS. Any HRT use was not associated with DCIS in this study but was inversely
associated with invasive disease, with some evidence of a stronger association for greater
than 10 years of HRT use. Odds ratios were also more strongly inverse for IBC compared to
DCIS for current but not former HRT use (data not shown). Younger age at menopause
(<40) was inversely associated with both invasive disease and DCIS, although the strength
and consistency of the relationship was more apparent for IBC. Similarly, older ages at
menarche showed inverse associations with both DCIS and IBC but were more consistent
for IBC. Each increase in age at menarche was associated with a decrease in odds ratio for
IBC.
DCIS comedo vs. non-comedo
Experiencing at least one full-term pregnancy was inversely associated with comedo DCIS,
with stronger inverse associations for increasing numbers of full-term births (Table 3). Non-
comedo DCIS were inversely associated with three or more full-term births, but the
association was weaker than the corresponding odds ratio for comedo DCIS. Ever
breastfeeding was not significantly associated with either comedo or non-comedo DCIS,
though the OR was less than 1.0 for comedo but not non-comedo DCIS. Similarly, odds
ratios for ever use of hormone replacement therapy were not statistically significant for
either DCIS subtype, although the association was inverse for comedo but not non-comedo
DCIS. Odds ratios for recent and former HRT were more strongly inverse for comedo
compared to non-comedo DCIS (data not shown). When comedo and non-comedo DCIS
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cases were compared in a case-case analysis, ORs were statistically significant only for
duration of OC use; however, these associations were based on small numbers of cases.
Results did not differ substantially when we adjusted for history of screening mammography
(data not shown).
DISCUSSION
Using a large, population-based study of carcinoma in situ of the breast and invasive breast
cancer, we evaluated known hormonal and reproductive risk factors for invasive breast
cancer to determine whether they are also risk factors for DCIS. Parity and younger age at
first full-term pregnancy, and younger age at menopause (<40) were inversely associated
with both DCIS and IBC, while older age at menopause was positively associated with IBC
only, and older age at menarche was inversely associated with IBC only. Ten or more years
of oral contraceptive use showed a positive association with comedo-type DCIS and
invasive breast cancer but an inverse association for non-comedo DCIS.
When DCIS cases in our study were separated into the two main histologic subtypes,
comedo and non-comedo, comedo-type DCIS associations paralleled invasive results more
frequently than non-comedo DCIS. Specifically, parity, lactation, and HRT use were
inversely associated with both comedo DCIS and IBC. These results support the theory that
DCIS is not a uniform disease, and similarities in risk factors between comedo DCIS and
invasive breast cancer are in agreement with data showing that comedo DCIS is more
closely related to invasive breast cancer (27).
Many studies examined reproductive risk factors for invasive breast cancer and DCIS, but
differences in study designs, methods, and populations make comparisons of results
difficult. Including both DCIS and invasive cases from the same population circumvents
many of those issues, allowing for direct comparison between odds ratios. Six previous
studies of reproductive or hormonal risk factors for DCIS have included invasive cases as
well (28-33), and as with the current study, these studies found few differences in risk
factors between DCIS and invasive disease. Two other studies examined reproductive risk
factors in CIS cases only (34, 35). Parity (28-31, 33-35), young age at first full-term
pregnancy (28, 29, 31-34), and older age at menarche (28, 33) were inversely associated
with both outcomes, while older age at menopause and postmenopausal hormone
replacement therapy use (31, 33) have been positively associated with both forms of cancer.
Only one other published study examined reproductive risk factors for comedo and
noncomedo DCIS specifically, which were limited to parity and age at first full-term birth
(29). In that study, the authors found no association with parity and either DCIS subtype and
a positive association between comedo DCIS and age at first birth of 25 or higher (OR=1.38,
95% CI 1.02-1.88 for age 25-29, OR=1.63, 1.05-2.52 for age 30+). In contrast, parity
showed a stronger inverse association with comedo DCIS than with non-comedo or all DCIS
combined in our study, especially for two or more full-term pregnancies.
Evidence suggests that a woman's breasts reach full maturity after a full-term pregnancy,
making the cells less vulnerable to neoplastic changes (36). In the current study, ever having
a full-term pregnancy was inversely associated with invasive breast cancer. For DCIS, the
protective association was limited to those with a first full-term pregnancy under age 26.
Nine previous DCIS risk factor studies included parity and age at first full-term pregnancy,
all of which found results similar to ours (29-31, 33-35, 37, 38).
In the current study, lactation was inversely associated with IBC but showed no overall
association with DCIS. Only three other studies assessed associations with lactation and
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DCIS (30, 31, 35). Two found no association between breastfeeding and either DCIS or IBC
(30, 31), but in the third study, lactating for 24 months or more was associated with DCIS
(OR=2.00, 95% CI 1.11-3.60) (35). These varied findings may be due to differences in
lactation practices in the underlying populations. For instance, breastfeeding is more
prevalent and done for longer periods of time in China, where a significant inverse
association with lactation for more than 24 months was found for IBC (OR=0.46, 0.27-0.78)
(39).
Estrogen levels play an important role in reproductive events. Increase in estrogen leads to
menarche, and decreasing levels precipitate menopause. In addition, estrogen augmented by
progesterone has been shown to promote cell division, which increases the chance of mutant
cell growth (40). The current study results support this theory for both invasive breast cancer
and DCIS. Other studies that examined age at menarche and menopause found mixed
results. Three found no association between age at menarche and DCIS or invasive disease
(30, 34, 38). Of the two others reporting an association with age at menarche, Longnecker et
al used the youngest age group as the referent and found an inverse association with the
oldest age group (≥14 years) for both DCIS and invasive disease (OR=0.36, 0.15-0.87 for
DCIS, OR=0.61, 0.43-0.86 for invasive) (33), while Kerlikowske et al found a positive
association for the youngest age at menarche group (≤12 years) compared with those over
age 12 at menarche for invasive breast cancer only (OR=1.9, 1.4-2.7) (28). Menopause at
age 55+ was associated with DCIS (OR=1.53, 1.07-2.18) and IBC (OR=2.85, 1.37-6.35) in
the Longnecker et al study (33) but was associated with DCIS only in the study by Claus et
al (2001) (OR=1.71, 1.05-2.77). Age 45+ at menopause showed an increased association
with IBC only in the study by Trentham-Dietz et al (OR=1.03, 1.02-1.04 continuous per
year). One other study reported no association between age at menopause and either DCIS
or invasive disease (38).
The link between oral contraceptive use and breast cancer risk is less clear than with other
hormonal risk factors, especially among earlier-stage cancer. OC use showed no association
with DCIS or invasive disease in our study. All other studies that included both invasive and
DCIS cases found OC use was positively associated with IBC but not associated with DCIS
(31, 32, 41-43).
Although most other studies found that postmenopausal hormone replacement therapy was
positively associated with either DCIS or invasive breast cancer (31, 33, 34, 38, 44, 45),
HRT was inversely associated with IBC in our study, especially among those using HRT for
longer than 10 years. While this difference is puzzling, one explanation may be that we did
not differentiate between estrogen-only and estrogen-plus-progestin regimens. Two studies
which did examine HRT (estrogen and progesterone) and ERT (estrogen only) separately
found HRT associated with DCIS (OR=1.75, 95% CI 1.10-2.80 for Longnecker et al,
OR=2.3, 95% CI 1.3-3.9 for Schairer et al) but not with IBC (OR=1.14, 95% CI 0.91-1.43
and OR=1.1, 95% CI 0.9-1.4, respectively), while ERT was not associated with either
outcome (33, 45). A third study found ERT associated with IBC (OR=2.22, 1.18-4.17) but
not with DCIS and no association between HRT and either outcome (44). Another reason for
the difference between our results and those of other studies for HRT could be that a higher
percentage of our controls reported ever using HRT (50.3% for invasive, 63.9% for DCIS)
than the rate of HRT use in the general population (44%) (46).
A strength of the CBCS is that the population base in North Carolina includes African
Americans, who have been under-represented in previous epidemiologic studies of DCIS.
Differences between our results and other studies could reflect the underlying study
populations. For example, in our study population, African-American participants were
statistically significantly less likely to use postmenopausal hormone replacement therapy
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than Caucasians (47). Unlike the invasive portion of the CBCS where African Americans
were over-sampled, all cases of DCIS were eligible the in-situ portion of the study. The
number of minority participants with DCIS was not sufficient to conduct separate analyses
by race, so it is difficult to draw specific conclusions about risk factors for DCIS among
African Americans. In addition, overall response rates in our study were lowest for African-
American controls, suggesting that future studies should focus recruitment efforts on
increasing participation among minorities and controls in particular.
Selection bias was a potential issue for this study, since case participants could have had
better and more frequent access to healthcare and therefore mammography screening.
However, the data was analyzed stratified on frequency of doctor's visits and having had a
mammogram in the two years previous to participation in the study, and neither affected the
odds ratios (data not shown). Finally, because there is no universal classification system for
DCIS pathology, comedo and non-comedo cases could have been misclassified.
Unpublished data by the authors of the current study on DCIS subtype classification errors
indicate that pathologist errors are predominantly in favor of the more severe (comedo)
category. Therefore, a sensitivity analysis was conducted by increasing the number of
comedo cases using the methods described by Rothman and Greenland (48), which
determined that over one-third would have to be incorrectly classified to have had any
impact on the results.
It has already been established that women with non-comedo type DCIS should be evaluated
and treated using criteria different from those of the more aggressive types of DCIS. Our
results support this conclusion, suggesting that comedo type DCIS may be more similar to
invasive breast cancer with regard to underlying etiology. However, future studies will need
to include larger numbers of both DCIS subtypes in order to clarify associations between
each subtype and potential risk factors. With more women being diagnosed at earlier stages
of breast cancer, large epidemiologic studies of DCIS with sufficient power to stratify on
comedo versus non-comedo histology are feasible and likely to be highly informative.
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